CSI Market
Sign In | Register

Navidea Biopharmaceuticals Inc (NAVB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NAVB quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Navidea Biopharmaceuticals Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income-15.18
Depreciation & amortization0.05
Amortization of Other Assets0.26
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.28
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.07
Share-based Compensation0.30
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gains On Dispositions Of Discontinued Operations Net Of Tax Non Cash-
Amortization Of Debt Discount Premium And Debt Related Commitment Fees And Debt Issuance Costs-
Increase Decrease Inventory Reserve-
Change In Fair Value Of Financial Instruments-
Issuance Of Stock To Defined Contribution Plan For Employer Matching Contribution0.04
Depreciation And Amortization Of Property And Equipment-
Write Off Of Deferred Debt Issuance Cost-
Prepayment Premium And Debt Collection Fees Of Long Term Debt-
Gain On Forgiveness Of Accounts Payable-
Gain Loss On Forgiveness Of Accounts Payable-
Interest Costs Capitalized-
Noncash Lease Expense-
Operating Lease Right Of Use Asset Amortization Expense0.11
Increase Decrease In Contract With Customer Liability0.76
Income taxes0.00
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Receivables0.09
Increase (Decrease) in Accounts Payable0.70
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.35
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.95
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.21
Discontinued operations0.00
Net Cash flow from Operating Activities-8.99
Investing Activities
Capital Expenditures-0.39
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities0.00
Real Estate Investments0.00
Equity Method Investment Payment Upon Termination Of Joint Venture-
Proceeds From Return Of Equipment-
Proceeds From Sale Of Payments To Acquire Property Plant And Equipment-
Patent And Trademark Costs-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.39
Financing Activities
Short-term debt Net2.50
Other borrowing transactions-0.01
Long-term debt - borrowings0.00
Long-term debt - repayments-0.52
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock6.17
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-4.23
Payments Of Debt Related Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations4.23
Cash Provided By Used In Investing Activities Discontinued Operations-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.38
Total Cash Flow-2.24
4 historic quarters locked

Sign in to unlock the full Navidea Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Navidea Biopharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-23-032052

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License